As International Women’s Day (IWD) approaches, fresh data shows the women’s health therapeutics market booming with demand for precise, tech‑enabled care – yet gaps in evidence and access persist despite the pharmaceutical industry’s growing role. New analysis from Vantage Market Research highlights shifts in trial design, digital tools and biologics reshaping care for half the world’s patients, but not without stubborn hurdles.
From niche to notable
Women’s health therapeutics, once treated as a niche within primary care, are now a core growth pillar for many pharmaceutical companies, underpinned by rising female life expectancy and more women living with chronic conditions such as endometriosis, osteoporosis and menopause‑linked disease. Market forecasts from Precedence Research estimate the global women’s health therapeutics market will grow to about $48bn in 2026 to $66bn by 2034, at a compound annual growth rate just above 4%.
A notable shift is the move away from “one dose fits all” regimens towards therapies tuned to genetic profiles, hormone cycles and patient history. This is reinforced by pressure to correct the historic under‑representation of women in clinical trials, with recent analysis in Nature and elsewhere suggesting women still account for only around 29–41% of trial participants on average, and closer to one in three in some early‑phase studies.
Data, digital tools and policy
Sponsors are having to adapt trial timelines and protocols to account for hormone cycles, pregnancy potential and sex‑stratified analyses, raising cost and complexity but promising data that better reflects real‑world use. Policy makers are also hard‑wiring women’s health into national strategies. In England, the government has pledged to renew its Women’s Health Strategy set out in 2022 with a stronger focus on conditions such as endometriosis, PCOS and long gynaecology waits.
As Wes Streeting, UK Health Secretary, put it in a recent update: “Too many women are still subject to a system that doesn’t listen to their experiences or understand their needs… Our renewed strategy will set out our longer-term vision so every woman gets the healthcare she deserves, when she needs it.”
Digital health is emerging as a key enabler, with apps, wearables and telemedicine now used to track cycles, pregnancy and menopause symptoms, while also giving clinicians richer data between visits, including in underserved areas. On the therapeutic side, biologics, advanced hormonal approaches and long‑acting injectables or patches aim to improve adherence and cut side‑effects, while targeted and immune‑based agents in breast and ovarian cancer have an increasing pipeline presence.
IWD puts investment gap in focus
Despite this momentum, the market faces pressure from high R&D costs, complex trials and pricing competition, especially as generics enter the fold. Ireland’s recent move to ring‑fence funding for women’s health research highlights efforts to tackle potential hurdles. Jennifer Carroll MacNeill, Minister for Health, warned that historic underfunding has left “treatments based on male data” and backed projects to improve outcomes “across all stages of life”.
At the same time, a World Economic Forum analysis found that women and girls, nearly half the global population, receive only around 6% of health R&D and digital health investment, while a recent Forbes review described women’s health as a $360bn “ghost market” in unmet demand.
For pharma, as IWD on 8 March nears, women’s health therapeutics are no longer a side line, but a test of how far the sector will go on inclusive research, digital‑first care and long‑term partnership with patients who have, for too long, been asked to fit a male norm.
